Clinical Trial Update: Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 [Phase 4]

View source ↗

Summary

This report covers a completed Phase 4 trial and its 24-week open-label extension evaluating the rivastigmine transdermal patch in patients with severe Alzheime…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon Patch (rivastigmine transdermal patch) (rivastigmine transdermal patch)

Snippet

Sponsor: Novartis | Conditions: Alzheimer's Disease | Phase 4 | Status: COMPLETED | Results posted: 2013-02-11